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Abstract 
Background: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a novel mode of 
intraperitoneal (IP) drug delivery claiming high IP tissue concentrations with low systemic uptake. 
The aim was to study inflammatory response and systemic toxicity after PIPAC. 
Methods: Retrospective monocentric analysis of a consecutive cohort of PIPAC patients between 
January 2015 and April 2016. Detailed hematological and biochemical analysis was performed the 
day before surgery and once daily until discharge. Comparative statistics were performed using 
Mann-Whitney U test and Wilcoxon signed ranked test. 
Results: Fourty-two consecutive patients underwent a total of 91 PIPAC procedures. Twenty 
patients received oxaliplatin and 22 cisplatin+doxorubicin (37 vs. 54 procedures). Creatinine, AST 
and ALT were not significantly altered after PIPAC (p=0.095, p= p=0.153 and p=0.351) and not 
different between oxaliplatin and cisplatin+doxorubicin regimens (p=0.371, p=0.251 and p=0.288). 
C-reactive protein (CRP) and procalcitonin (PCT) increased on post-operative day (POD) 2: ∆max 
29±5 mg/L (p<0.001) and ∆max 0.05±0.01 μg/L (p=0.005), respectively. Leucocytes increased at 
POD 1: ∆max 2.2±0.3 G/L (p<0.001). Albumin decreased at POD 2: ∆max -6.0±0.5 g/L (p<0.001). 
CRP increase correlated positively with Peritoneal Cancer Index (tumor load) (ρ =0.521, p<0.001).  
Conclusion: PIPAC was followed by a modest and transitory inflammatory response that was 
commensurate to the disease extent. No hematological, renal or hepatic toxicity was observed even 
after repetitive administration. 
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Introduction 
Intraperitoneal (IP) chemotherapy is a treatment 
alternative for selected patients with peritoneal 
carcinomatosis (PC) [1, 2]. The rationale for IP 
treatment is to obtain higher intraperitoneal 
concentrations with low systemic uptake to reduce 
systemic toxicity [3, 4]. Intraabdominal complications, 
hematological but also renal toxicity, and a profound 
inflammatory response are typical adverse events of 
both types of conventional treatment, namely 
hyperthermic IP chemotherapy by lavage (HIPEC) 
and IP chemotherapy administered by an implantable 
catheter [5-7]. 
Pressurized Intraperitoneal Aerosol Chemo-
therapy (PIPAC) is a novel minimal-invasive 
approach for intraperitoneal drug delivery. 
Administration as an aerosol allows for better 
distribution within the abdominal cavity, and tissue 
concentrations of the therapeutic agents are increased 
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under pressure conditions (pneumoperitoneum) 
despite lower concentrations than for conventional 
intraperitoneal chemotherapy [1].  
The aim of this study was to assess 
hematological, renal and hepatic toxicity in a 
consecutive cohort of PIPAC patients and to measure 
inflammatory response after PIPAC. 
Methods  
 PIPAC was introduced at the University 
Hospital of Lausanne (CHUV) in January 2015. All 
patients entered a prospectively maintained coded 
online data base. Considered for PIPAC treatment 
were patients with isolated PC of various origins with 
persistence or progression after standard treatment 
including surgery and systemic chemotherapy (≥2 
lines for most patients). All indications were 
confirmed during multidisciplinary tumor board. 
PIPAC treatment alone was preferred and combined 
intraperitoneal and systemic treatment was 
exceptional. The present analysis on toxicity and 
inflammatory response includes all consecutive 
patients operated until April 2016. Feasibility, 
postoperative outcomes and quality of life of this 
cohort were reported recently [8, 9]. The study was 
approved by the Institutional Review Board 
(N°2016/0274) and all patients provided written 
consent for utilization of their data. This study was 
registered online (www.researchregistry.com #UIN: 
2197). STROBE criteria [10] were adhered to for 
conduction and reporting of the study. The study was 
conducted in accordance with the principles of the 
Declaration of Helsinki. 
PIPAC procedure and treatment algorithm  
Methodology and surgical approach of PIPAC 
have been reported elsewhere [8, 11]. Briefly, three 
PIPAC treatments were scheduled at 6-week intervals 
upon decision of multidisciplinary tumor board. 
Every patient was seen in outpatient consultation 4 
weeks after PIPAC treatment for monitoring of 
complications and evaluation of contraindications to 
proceed with PIPAC procedures. Thoraco-abdominal 
computed tomography (CT) was performed 4 weeks 
prior to first PIPAC and between PIPAC#2 and 
PIPAC#3 to rule out extraperitoneal disease and a 
third CT was scheduled 2 months after completion of 
3 PIPAC treatments [8]. Intraperitoneal chemotherapy 
regimens were defined on individual basis adhering 
closely to the empiric definitions of the German 
pioneer group suggesting oxaliplatin monotherapy 
(92 mg/m2 body surface) for colorectal primary and 
combined cisplatin (7.5 mg/m2 body surface) and 
doxorubicin (1.5 mg/m2 body surface) for ovarian 
and gastric origin [8, 11, 12]. IP treatment was 
administered for 30 minutes at 37°C and with a 
standard laparoscopic pressure of 12 mmHg. After 
treatment, pneumoperitoneum with potential 
remaining cytostatics was evacuated via a closed 
system including two microparticle filters [2]. 
Assessment of postoperative toxicity and 
inflammation  
Blood drawings were performed in a fasting 
state following standardized institutional guidelines, 
the day before surgery and once daily until discharge.  
Toxicity was assessed by measuring creatinine 
(Crea) (μmol/L), aspartate aminotransferase (AST, 
institutional reference (IR): <50 U/L) and alanine 
aminotransferase (ALT, IR: <50 U/L). Acute renal 
dysfunction was defined as post-treatment creatinine 
increase >50% according to Risk, Injury, Failure, Loss of 
kidney function, and End stage kidney disease (RIFLE) and 
Acute Kidney Injury Network (AKIN) classification [13, 
14].  
Inflammatory response was assessed measuring 
leukocyte (Lc) counts (IR: 4.0-10.0 G/L), C-reactive 
protein (CRP, IR: <5 g/L), procalcitonin (PCT, IR: 
<0.06 μg/L) and albumin (Alb, IR: 32-46 g/L). 
Maximal values were considered for Lc, CRP and 
PCT. Relevant postoperative inflammation was 
defined according to literature as Lc >12 G/L, CRP 
>140 g/L and PCT >0.25 μg/L [15-17]. Maximal 
difference between the pre- and postoperative values 
was used for albumin (ΔAlb) and a cut-off value of 
>10 g/L was used to indicate important inflammatory 
response [18]. Temperature was measured 4 times per 
day during the hospitalization.  
Predefined clinical questions 
Several comparisons and statistical correlations 
were defined a priori: Evaluation of cumulative 
toxicity after repetitive PIPAC applications and 
comparison of systemic inflammation between 
PIPAC#1, PIPAC#2 and PIPAC#3. Comparison of 
inflammation and toxicity response between patients 
treated with oxaliplatin vs. cisplatin and doxorubicin. 
Correlation between tumor load as assessed by the 
Peritoneal Cancer Index (PCI) and post-inflammatory 
response [19]. 
Statistical analysis 
Continuous variables were presented as mean 
with standard error of the mean (SEM) or median 
with range or interquartile range (IQR) for skewed 
data. Categorical variables were reported as 
frequencies (%) and compared with chi-square test. 
Wilcoxon signed ranked test, Mann–Whitney test and 
Kruskal-Wallis test were used for statistical 
comparisons. Statistical correlations were tested by 
use of Pearson’s rank correlation. All statistical tests 
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were two-sided and a level of 0.05 was used to 
indicate statistical significance. Statistical analyses 
were performed and figures were produced with 
SPSS v20 statistical software (Chicago, IL, USA) and 
GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, 
CA, USA). 
Results 
Patients’ characteristics and details of the 
procedures 
The present cohort included 42 consecutive 
patients who underwent a total of 91 PIPAC 
procedures, distributed in 2 groups receiving 
oxaliplatin vs. cisplatin+doxorubicin, respectively. 
The oxaliplatin group was composed of 20 patients 
(37 procedures) with colorectal primay (15), small 
bowel cancer and pseudomyxoma (1 each), and 3 
patients with gastric cancer. For the latter group, 
medical oncologists decided on individual basis to 
deviate from the empirical protocol (twice due to 
contraindications). The remaining 22 patients (21 
ovarian, 1 mesothelioma; 54 procedures) received 
cisplatin+doxorubicin according to recommendations. 
Baseline characteristics are displayed in Table 1. 
Surgery typically required 2 trocars for a median 
duration of 94 (89-108) minutes, whereas median PCI 
was 10 [8, 9]. 
Toxicity 
Creatinine level was not significantly altered 
after PIPAC procedures at post-operative day (POD) 
2: ∆max -3±1μmol/L (p=0.095). Based on liver 
enzymes AST and ALT on POD 2, no hepatotoxicity 
was caused by PIPAC treatment: ∆max -13±4U/L 
(p=0.153) and ∆max 4±3U/L (p=0.351) respectively. 
Differences in hepato-renal impact comparing the two 
regimens were not significant as detailed in Figure 1. 
Likewise, no difference was noted when comparing 
consecutive PIPAC procedures for all three 
parameters (Figure 2). 
Seven (17%) and 6 (14%) patients surpassed 
institutional thresholds for AST and ALT, 
respectively. There was no lasting effect. No patient 
presented acute kidney injury according to RIFLE 
criteria or AKIN classification. 
 
Table 1. Baseline demographics of patients treated with 
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)  
 Overall 
(n=42) 
Oxaliplatin  
(n=20) 
Cisplatin +Doxorubicin 
(n=22) 
Demographics    
Age (years) 66 (59-73) 62 (53-73) 68 (63-75) 
Gender (male) (%) 8 (19) 8 (40) - 
BMI (kg/m2) 22.5 (20-25) 21.5 (19-25) 22.7 (22-28) 
Cancer origin    
Colorectal (%) 15 (36) 15 (75)  - 
Gastric (%) 3 (7) 3 (15) - 
Ovarian (%) 21 (50) - 21 (95)  
Other (%) 3 (7) 2 (10) 1 (5) 
Median (IQR) for age and BMI. BMI: body mass index. 
 
Inflammatory response 
CRP and PCT increased on POD 2: ∆max 29±5 
mg/L (p<0.001) and ∆max 0.05±0.01 μg/L (p=0.005), 
respectively. Leucocytes increased at POD 1: ∆max 
2.2±0.3 G/L (p<0.001). Albumin decreased at POD 2: 
∆max -6.0±0.5 g/L (p<0.001).  
The profiles of inflammatory markers displayed 
by chemotherapy regimen are illustrated in Figure 3. 
For both regimens CRP and Lc count were 
characterized by an increase on POD 2 and POD 1 
respectively (Figures 3A and 3C). Conversely, 
albumin level decreased by POD 2 (Figures 3D). Both 
regimens influenced markers’ kinetics similarly 
except for PCT (where oxaliplatin induced a higher 
increase than cisplatin+doxorubicin) (Figure 3C).  
 
 
Figure 1. Hepato-renal toxicity after Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) treatment by chemotherapy regimen 
(Oxaliplatin vs. Cisplatin and Doxorubicin)  Oxaliplatin,  Cisplatin + Doxorubicin, Bars represent standard error of the mean (SEM), IR (Institutional 
Reference, U/L) Hepato-renal toxicity after PIPAC treatment by chemotherapy regimen until postoperative day (POD) 4. AST – aspartate aminotransferase, ALT – 
alanine aminotransferase. 
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Figure 2. Hepato-renal toxicity after repetitive Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) procedures. Hepato-renal toxicity 
under PIPAC treatment represented by AST, ALT and Creatinine levels. Δ represents Δmax. No significant difference (p<0.05) was found for repetitive PIPAC 
applications. AST – aspartate aminotransferase, ALT – alanine aminotransferase. 
 
 
Figure 3. Inflammatory response after Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) by chemotherapy regimen.  Oxaliplatin 
Cisplatin +Doxorubicin. Inflammatory response under PIPAC treatment by chemotherapy regimen until postoperative day (POD) 4. Bars represent standard error 
of the mean (SEM). 
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Figure 4. Inflammatory response after repetitive Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) procedures. Inflammatory 
response under PIPAC treatment represented by C-reactive protein at post-operative day (POD) 2, Procalcitonin at POD 2, Leukocytes at POD 1 and Albumin at 
POD 2. Bars represent standard error of the mean (SEM). Δ represents Δmax.No significant difference was found when inflammatory response was compared before 
and after different PIPAC applications. 
 
Of note, one patient (2%) presented leukopenia 
after PIPAC 1 with spontaneous resolution within 2 
days. One patient had fever >38° after PIPAC #3 also 
with spontaneous resolution. 
In 17 patients (40%), relevant postoperative 
inflammation as defined under methods was observed. 
Ten patients (24%) showed increased Lc count above 
12G/L, 2 patients (5%) increased CRP level above 
140g/L and 3 patients (7%) PCT level above 0.25 
μg/L. Only one patient (2%) had concomitant 
relevant increase of Lc and CRP levels and another 
patient (2%) of Lc and PCT levels.  
The extent of inflammatory response after 
consecutive PIPAC procedures was similar with no 
significant difference for any of the candidate markers 
(Figure 4). 
Using CRP and PCI as respective surrogate 
markers of inflammation and tumor burden, the 
inflammatory response induced by PIPAC correlated 
positively with tumor load (ρ =0.521, p>0.001) (Figure 
5). 
 
 
Figure 5. Tumor load and post- Pressurized Intraperitoneal Aerosol 
Chemotherapy (PIPAC) inflammation. C-reactive protein (CRP) was 
plotted against the extent of peritoneal disease (measured by the Peritoneal 
Cancer Index (PCI)). 
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Table 2. Synopsis of systemic toxicity and inflammation after different treatments for peritoneal carcinomatosis 
 Toxicity 
Renal 
 
Hepatic 
 
Hematologic 
 
Other 
Inflammatory 
Reaction 
Drug 
Concentration 
       
Systemic 
chemo  
Creatinin 
increase:5-10%* 
AST/ALT increase: 
36-54%* 
Neutropenia: 42% [40] 
Thrombopenia: 3-4% 
[41] (III-IV) 
Neurotoxicity 
up to 90% [42] 
(dose-dependent)  
Fever 25% [40] Oxaliplatin: 
85 mg/m2 
 
 
HIPEC 
 
Creatinin increase: 
18% [43] 
Nephro-toxicity: 
6% [43] 
(III-V)* 
 
Hepato-toxicity** 
36% (III) 50% (II) [44] 
 
Neutropenia: 27% [45] ** 
40% [46] *** 
 
Surgical morbidity: 
34% (III+IV) 
4% mortality [5] 
 
CRP at 48h: 180mg/L 
[47] 
 
*Cisplatin  
75 mg/m2 
+/-Mitomycin-C  
10 mg/m2 
**Oxaliplatin  
460 mg/m2 
***Mitomycin-C 0.8 
mg/kg 
 
IP catheter 
 
Nephro-toxicity 
7% [32]  
(III-IV) 
 
Hepato-toxicity 
3% [32]  
(III-IV) 
 
Leukopenia:  
40-76% [32, 33] 
Thrombopenia: 8-12% 
[32, 33]  
Anemia: 26% [33] 
 
Neurologic events: 
19% [32] (III-IV)  
 
Infection: 16% [32] 
(III-IV)  
 
Cisplatin  
100 mg/m2 +/- 
Paclitaxel  
60 mg/m2  
 
 
PIPAC 
 
None 
 
TransitorygGT increase 
[36] 
AST/ALT increase: 
14-16% 
 
None 
 
Surgical morbidity: 
9% (mainly I+II) [8] 
 
CRP at 48h: 
45mg/L* 
CRP at 48h 
15mg/L** 
 
*Oxaliplatin  
92 mg/m2 
**Cisplatin  
7.5 mg/m2 + 
Doxorubicin  
1.5 mg/m2 
Chemo – chemotherapy, HIPEC – Hyperthermic Intraperitoneal Chemotherapy, IP – intraperitoneal, PIPAC – Pressurized Intraperitoneal Aerosol Chemotherapy, AST - 
aspartate aminotransferase, ALT – alanine aminotransferase, CRP – C-Reactive Protein, gGT – gamma Glutamyltransferase Severity grades of complications are displayed in 
brackets. 
 
Discussion  
In this cohort, PIPAC was followed by a modest 
and transitory inflammatory response that was 
commensurate to the disease extent. No 
hematological, renal or hepatic toxicity was observed 
even after repetitive administration. 
The findings of the present study need to be 
discussed in the setting of four available treatment 
options for advanced peritoneal carcinomatosis: 
systemic chemotherapy, hyperthermic intraperitoneal 
chemotherapy (HIPEC) after cytoreductive surgery 
(CRS), intraperitoneal catheter chemotherapy and 
PIPAC (Table 2). Of note, it is not the intention to 
formally compare those treatment approaches due to 
their very different nature but to provide a 
comprehensive overview on what is known on 
toxicity and inflammatory response under the 
respective treatment. 
Systemic chemotherapy represents a first line 
therapy in patients with peritoneal carcinomatosis, 
especially with extraperitoneal spread of tumor [20]. 
New drugs such as antibodies or irinotecan allowed 
for better survival in recent years, but 
pharmacokinetic limitations such as peritoneum- 
plasma barrier impede proper penetration of 
cytostatics in peritoneal tumor nodes [21, 22]. 
Parenteral drug concentrations need thus to be high to 
achieve a therapeutic effect. Up to tenfold higher 
concentrations were described for systemic 
chemotherapy as compared to intraperitoneal use, 
and side effects for most therapies are common [4]. 
Chemotherapy induced peripheral neuropathy 
represents a well-known side effect of platin-based 
chemotherapy regimens [23]. Up to 90 % of patients 
are affected after systemic oxaliplatin treatment, and 
treatment options remain scarce [24, 25]. Cisplatin is 
eliminated by the kidney, and dose-dependent renal 
toxicity of cisplatin and its metabolites has been 
described [26]. Standard systemic doses of 75-100 
mg/m2 lead to tubular necrosis in up to 30% of 
patients, and renal failure might be the ultimate 
consequence [26]. Taken together and in the light of 
pharmacokinetic limitations of systemic therapy for 
the treatment of peritoneal carcinomatosis, alternative 
locoregional treatments were considered. 
Cytoreductive surgery combined with HIPEC 
represents the only potentially curative treatment 
option in few selected patients who are fit enough to 
tolerate this complex treatment option with important 
morbi-mortality [5, 27]. Intraperitoneal administration 
permits higher drug concentration with better tumor 
penetration as compared to systemic chemotherapy 
[28, 29]. Even if no formal consensus exists, common 
drugs for HIPEC are cisplatin, mitomycin C and 
oxaliplatin in different combinations and doses, 
depending on the primary tumor [27]. In high volume 
centers, mortality rates of up to 5.8%, major 
complication rates between 12-52% and hematological 
toxicity of up to 28% of patients were described using 
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these regimens [27]. Irinotecan was added in more 
recent years; neutropenia and thrombopenia at the 7th 
postoperative day occurred in 11% of patients in a 
cohort treated with a combination of Irinotecan and 
Oxaliplatin [30]. In a recent study using the same 
regimen, hematologic toxicity was even higher with 
41% neutropenic (<500/μl) patients and 26% with 
grade 3 thrombopenia (<50000/μl) [31]. PIPAC as a 
minimally invasive treatment option might thus 
represent an alternative for frail patients who are not 
eligible for this curative approach given the multitude 
of surgery- and drug-related side effects. 
Repetitive administration through intraperito-
neal catheters in an adjuvant setting after optimally 
debulked stage III ovarian cancer represents an 
alternative to HIPEC [32]. Intraperitoneal administra-
tion of paclitaxel and cisplatin combined with 
intravenous paclitaxel significantly improved surv-
ival compared to patients receiving the same drugs 
exclusively intravenously [32]. However, patients in 
the intraperitoneal group experienced more pain and 
presented more hematologic, gastrointestinal and 
neurologic toxic effects (Table 2). A former study 
compared intraperitoneal cisplatin to intravenous 
cisplatin to demonstrate improved survival and fewer 
toxic effects in the intraperitoneal group [33]. 
PIPAC combines the advantages of 
intraperitoneal administration, allowing for higher 
tumor concentrations [28] and administration under 
pressure, which permits higher intra-tumoral 
concentrations despite lower drug doses [3]. In a pilot 
study of the pioneer group from Herne, Germany, 
peripheral drug concentrations of doxorubicin were 
very low with 4.0-6.2 ng/ml after PIPAC treatment 
within standard conditions [1]. As a consequence, 
only modest and transitory inflammatory response 
was observed in former studies and in the present 
cohort [34-36]. This response might be a consequence 
of drug-induced chemical peritonitis after 
intraperitoneal vaporisation, which provides an 
explanation for abdominal pain as main postoperative 
complaint after PIPAC [34]. Two centers reported on 
toxicological aspects of PIPAC treatment [35, 36]. 
Similar to the present findings, Blanco described liver 
and renal parameters within the normal range with no 
cumulative toxicity [35]. Similarly, an Italian group 
described no clinically relevant liver cytolysis without 
metabolic nor synthetic hepatic and renal dysfunction 
[36]. Both groups concluded that PIPAC caused less 
hepatic and renal toxicity than other chemotherapy 
delivery routes due to lower therapeutic doses and 
favorable kinetics [35, 36]. The present findings 
confirm the previously reported results. As a 
consequence of low toxicity, encouraging results 
regarding quality of life and tolerance of the 
procedure have been described by our group and by 
others [8, 9, 37]. 
 Several limitations of the present study need to 
be discussed beyond retrospective study design and 
small patient cohort. Given the very short median 
hospital stay, only few patients were available for 
blood drawings after POD 3 and inflammatory 
parameters beyond POD 3 should therefore not be 
considered representative for the entire PIPAC cohort. 
Systemic toxicity was low in the present study, which 
might be due to low administered drug 
concentrations. The proposed regimens did not derive 
from a dose escalation protocol and hence, drug 
choices and doses rely on empirical protocols. Three 
dose escalation studies however have been initiated in 
the meantime (NCT02475772, NCT03172416 and 
Eudra-CT 2016-003666-49). Since PIPAC is a very new 
technique, no long-term results are available to date. 
Despite favorable short-term results regarding clinical 
and histological response rates [34, 38, 39], sustained 
long-term impact of PIPAC under presently applied 
conditions needs yet to be proven. 
In conclusion, there was no relevant systemic 
toxicity after PIPAC with the current treatment 
standard even when repeatedly applied. Inflamm-
atory response was modest and transitory. It is 
important to repeat this type of studies for new 
treatment standards, especially when using higher 
drug concentrations. 
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